atazanavir (reyataz) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Atazanavir is the first once-daily protease inhibitor for the treatment of human immunodeficiency virus type 1 infection and should be used only in combination therapy, as part of a highly active antiretroviral therapy (HAART) regimen. In addition to being the most potent protease inhibitor in vitro, atazanavir has a distinct cross-resistance profile that does not confer resistance to other protease inhibitors. However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir.   NCATS

Chemistry

  • SMILES: COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc2ccc(cc2)c3ccccn3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
  • InChIKey: AXRYRYVKAWYZBR-GASGPIRDSA-N
  • Mol. Mass: 704.87
  • ALogP: 4.21
  • ChEMBL Molecules:
    atazanavir  
    atazanavir sulfate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$4.2472 - $48.5567

Australia

$5.1763 - $7.7641
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( atazanavir (reyataz), cobicistat (stribild) )

Alternative names

atazanavir | atazanavir sulfate | atazanavir sulfate / cobicistat | atazanavir sulphate | atazanavirum | atv | atz | bms-232632 | bms-232632-05 | cgp-73547 | latazanavir | reyataz | zrivada

Organizations (153)

Research & Development (142)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (31)

Approved Indications (2)


 

HIV Infections

Infections

Experimental Indications - Clinical Trial Phases 1-4 (31)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Antiretroviral Therapy, Highly Active (Phase 4)

Atazanavir Sulfate (Phase 1)

Bone Diseases, Metabolic (Phase 4)

Coronavirus Infections (Phase 2/Phase 3)

COVID-19 (Phase 2/Phase 3)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 2)

Drug Interactions (Phase 4)

Dyslipidemias (Phase 4)

Healthy Volunteers (Phase 4)

Hematologic Neoplasms (Phase 1)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 1)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

Hyperlipidemias (Phase 3)

Infections (Phase 4)

Inflammation (Phase 1)

Lipodystrophy (Phase 4)

Mitochondrial Diseases (Phase 4)

Neoplasms (Phase 1)

Neurodegenerative Diseases (Phase 1)

Protease Inhibitors (Phase 1)

Proteinuria (Phase 4)

SARS-CoV-2 (Phase 2/Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Substance-Related Disorders (Phase 1)

Tuberculosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 192
  • # of Trial Organizations: 142

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue